Relative Bioavailability Study of CX2101A for the Treatment of COVID-19
Status:
COMPLETED
Trial end date:
2024-05-25
Target enrollment:
Participant gender:
Summary
The study comprises three parts: single ascending dose (SAD) studies of CX2101A tablets at 40 mg, 100 mg, and 160 mg; a relative bioavailability (BA) study comparing single-dose administration of 100 mg CX2101A tablets and enteric-coated tablets; and a multiple ascending dose (MAD) study of CX2101A tablets. The BA study (100 mg) is integrated into the SAD study(Nested within the SAD protocol to optimize resource utilization).